Evommune (EVMN) Long-Term Investments (2025 - 2026)
Evommune (EVMN) reported Long-Term Investments of $95.5 million for Q1 2026, up 41.58% quarter-over-quarter from $67.5 million in Q4 2025.
Evommune (EVMN) Long-Term Investments (2025 - 2026) Analysis & Trends
Evommune (EVMN) has 2 years of Long-Term Investments data on file, last reported at $95.5 million in Q1 2026.
- Long-Term Investments for Q1 2026 came in at $95.5 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $95.5 million (changed N/A YoY), and the FY2025 annual result was $67.5 million, changed N/A from the prior year.
- Long-Term Investments rose to $95.5 million in Q1 2026 per EVMN's latest filing, from $67.5 million in the prior quarter.
- Over five years, Long-Term Investments peaked at $95.5 million in Q1 2026 and troughed at $67.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 5.17 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 5.75 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Evommune | 695.29 Mn | 483.82 Mn | - | 95.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 95.55 Mn |
| Dec 31, 2025 | 67.49 Mn |